Form 4: Esperion Therapeutics Executive Eric Warren Sells Shares to Cover Tax Obligations
SEC Filing
Esperion Therapeutics' Chief Commercial Officer, Eric Warren, sold 107 shares of common stock on October 17, 2024, to satisfy tax obligations related to vested restricted stock units.
Summary
- On October 17, 2024, Eric Warren, Chief Commercial Officer of Esperion Therapeutics, Inc., sold 107 shares of the company's common stock.
- The sale was executed at a price of $2.119 per share.
- The transaction was conducted to cover tax obligations arising from the vesting of restricted stock units.
- Following the transaction, Warren directly owns 162,552 shares of Esperion Therapeutics.
- The sale was reported on a Form 4 filing with the SEC.
Sentiment
Score: 5
Explanation: The document is a routine SEC filing related to an executive's stock sale for tax purposes. It doesn't convey any particularly positive or negative sentiment regarding the company's performance or outlook.
Industry Context
Executive stock sales are a common occurrence in publicly traded companies, often related to compensation and tax planning. The sale itself is unlikely to have a significant impact on the company's overall performance or stock price, given the small number of shares involved.
Key Dates
| Date | Description |
|---|---|
| February 28, 2022 | Date of execution of the Limited Power of Attorney. |
| 10/17/2024 | Date of stock sale transaction. |
| 10/18/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.